What is the life expectancy of someone with Koolen De Vries Syndrome / 17q21.31 Microdeletion Syndrome?

Koolen-de Vries Syndrome (KdVS), also known as 17q21.31 microdeletion syndrome, does not have a strictly defined reduced life expectancy, as most individuals live into adulthood. While health outcomes vary significantly depending on the severity of associated medical issues, early intervention and proactive management allow many people with Koolen-de Vries Syndrome to lead meaningful, fulfilling lives.

What factors influence the prognosis of Koolen-de Vries Syndrome?

The prognosis for someone with Koolen-de Vries Syndrome is highly individual. Because the 17q21.31 deletion can vary in size and the KANSL1 gene is critical for development, clinical presentation ranges from mild to complex. Life expectancy is primarily influenced by the presence and management of specific comorbidities, particularly congenital heart defects, renal anomalies, or severe epilepsy. With 8 members currently sharing their experiences on DiseaseMaps.org, we see that while the syndrome presents lifelong challenges, it is not inherently life-limiting in the way many progressive degenerative conditions are.

How does early care improve long-term outcomes?

Early diagnosis of Koolen-de Vries Syndrome is vital because it allows for the immediate implementation of multidisciplinary support. When medical teams proactively monitor for the most common health risks, they can prevent long-term complications. Key areas of focus for clinical management include:

• Cardiac evaluation: Regular screening for structural heart defects, which occur in approximately 30-50% of patients.


• Neurological support: Managing epilepsy and seizure disorders through targeted pharmacological treatment.


• Developmental therapies: Early access to speech, physical, and occupational therapy to maximize functional independence.


• Renal monitoring: Routine ultrasounds to detect potential kidney or urological abnormalities.

What is the focus on quality of life?

For families navigating Koolen-de Vries Syndrome, longevity is only one part of the journey. The clinical focus has shifted toward enhancing "healthspan"—the period of life spent in good health. Modern care for Koolen-de Vries Syndrome emphasizes social inclusion, communication support, and psychological well-being. As our understanding of the 17q21.31 microdeletion expands, the medical community is becoming better equipped to provide personalized care that prioritizes the unique strengths and needs of every individual.

Next steps

• Consult with a clinical geneticist to discuss the specific nature of the 17q21.31 deletion.


• Establish a multidisciplinary care team including a cardiologist, neurologist, and developmental pediatrician.


• Join the community at DiseaseMaps.org to connect with other families living with Koolen-de Vries Syndrome.


• Maintain a consistent schedule of health screenings to address potential complications early.

Medical disclaimer: This content is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Koolen-de Vries syndrome.


• Orphanet: 17q21.31 microdeletion syndrome (ORPHA:168571).


• OMIM (Online Mendelian Inheritance in Man): #610443 - Koolen-de Vries Syndrome.


• Koolen-de Vries Syndrome Foundation: Clinical management guidelines and patient resources.